Research Topic · Peer-Reviewed

Immunotherapy of Cancer

Cancer immunotherapy is a class of treatment that harnesses or modifies the immune system to recognize and destroy malignant cells, exploiting the immune system's capacity for specificity and memory to target tumours. It encompasses several major modalities, including immune-checkpoint inhibition that releases brake…

Curated from this journal's research 📚 7 peer-reviewed articles cited Cited 6× across the literature 🔖 ISSN 2577-137X 🗓 Reviewed July 2026

Overview

Cancer immunotherapy is a class of treatment that harnesses or modifies the immune system to recognize and destroy malignant cells, exploiting the immune system's capacity for specificity and memory to target tumours. It encompasses several major modalities, including immune-checkpoint inhibition that releases brakes on T-cell responses, adoptive cell therapies such as chimeric antigen receptor (CAR) T cells engineered to recognize tumour antigens, therapeutic and antigen-based vaccination, cytokine therapy, and antibody-based approaches. Advances at the interface of nanotechnology and immunotherapy seek to improve the delivery, targeting, and efficacy of cellular and molecular agents, extending the reach of CAR-T-cell and related technologies. Effective immunotherapy depends on understanding tumour antigens and the immune microenvironment, including oncofoetal antigens such as alpha-fetoprotein and its receptor, which inform both targeting and diagnosis. Immunomonitoring is integral to the field, with immunoassays and emerging immunogenomic approaches used to characterize antitumour immune responses, track treatment effect, and guide patient selection across cancer and infectious disease. Immunotherapy is applied across diverse malignancies and is increasingly integrated with surgery, chemotherapy, and other modalities, although its use does not uniformly alter the extent of other interventions. By directing immune effectors against cancer cells and enabling durable responses in some patients, cancer immunotherapy represents a distinct and rapidly developing therapeutic strategy, supported by advances in molecular targeting, delivery, and immunological monitoring.

Research published in this journal

7 peer-reviewed articles, ranked by relevance. Each links to its DOI.

2019

Avant Garde Alleviation -Cancer Immunotherapy

Bajaj AnubhaCorresponding author
MD. (Pathology) Panjab University, Department of Histopathology, A.B. Diagnostics, A-1, Ring Road , Rajouri Garden, New Delhi, 110027, India.
Clinical and Diagnostic Pathology doi:10.14302/issn.2689-5773.jcdp-19-3061

How this research is being cited

The 7 articles above have been cited 6 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.

A sample of recent works citing this journal's research on Immunotherapy of Cancer, linking to each citing work.

Editorial oversight

Curated from peer-reviewed research published in Immunization (ISSN 2577-137X).

Journal editorial board
Giuseppe Murdaca · Italy Harunor Rashid · Australia Ming Tan · United States

This page summarises published research for orientation; it is not medical or professional advice.